The Medicare GLP-1 Bridge demonstration launches July 1, 2026, offering eligible Part D beneficiaries access to Wegovy, Zepbound, and Foundayo for a flat $50 monthly copay. CMS has marketed the program as simple: enroll in a qualifying Part D plan, meet clinical criteria, and pay $50 per month. The reality is more complicated. Multiple ineligibility traps lie between the $50 promise and the pharmacy counter, and most of them do not surface until a provider submits the prior authorization request to the central processor.
This article is for manufacturer hub teams, field reimbursement specialists, provider-office access coordinators, and payer strategy teams who need to understand every pathway that can block a patient from the Medicare GLP-1 Bridge — and what to verify before the PA submission reaches the processor.
How the Bridge works and where patients get blocked
The Medicare GLP-1 Bridge is a short-term demonstration operating under Section 402(a)(1)(A) of the Social Security Amendments of 1967, as made applicable to Part D by Section 1860D-42(b) of the Social Security Act. It runs from July 1, 2026, through December 31, 2027. The program operates entirely outside the Part D benefit. Part D sponsors do not carry risk, do not process claims, and do not have to opt in. CMS contracts with Humana as the single central processor for prior authorization, claims adjudication, and pharmacy payment.
The patient pathway has three gates: (1) enrollment in an eligible plan type, (2) satisfaction of clinical criteria at the time of therapy initiation, and (3) successful prior authorization through the central processor. Each gate has specific traps.
Trap 1: Plan-type exclusion
CMS explicitly lists the plan types that qualify and the plan types that do not. This is the first and most fundamental ineligibility filter, and it is one that patients and prescribers frequently misunderstand.
Eligible plan types
- Standalone Prescription Drug Plans (PDPs)
- Medicare Advantage Coordinated Care Plans with drug coverage (MA-PD): HMO, HMO-POS, Local PPO, Regional PPO
- Special Needs Plans (SNPs)
- Employer/Union Group Waiver Plans (EGWPs)
- Limited Income Newly Eligible Transition (LI NET) program
- Dually eligible beneficiaries enrolled in any of the above plan types
Ineligible plan types
The following plan types cannot access the Bridge unless the beneficiary is also enrolled in a standalone PDP:
- Private Fee-for-Service (PFFS) plans
- Section 1876 cost contract plans
- Section 1833 health care prepayment plans
- PACE organizations
- Fallback plans
- Religious fraternal benefit plans
Why this trap matters in practice
A Medicare Advantage beneficiary who enrolled in a PFFS plan — which technically provides Part D coverage — will discover that the PFFS plan is not an eligible plan type for the Bridge. This is not intuitive, because PFFS plans do provide prescription drug coverage and count as Part D enrollment for most other purposes. The distinction exists because the Bridge demonstration is structured under specific Section 402 authority that defines eligible plan types more narrowly than the broader Part D program.
Patients in PACE organizations face a similar trap. PACE provides comprehensive Medicare and Medicaid benefits, including prescription drugs, but PACE is not a Part D plan. PACE enrollees who want Bridge access would need to also be enrolled in a standalone PDP — which is unusual, because PACE already covers prescriptions.
Hub teams should verify the patient's exact plan type before initiating a Bridge PA. Asking "do you have Part D?" is insufficient. The correct question is: "are you enrolled in a standalone PDP or an MA coordinated care plan (HMO, HMO-POS, or PPO) with drug coverage?"
Trap 2: BMI-timing mismatch
The Bridge clinical criteria require the beneficiary to have met a specific BMI threshold at the time they initiated GLP-1 therapy — not at the time of the PA request. This creates a timing trap that affects patients who have already been on GLP-1 therapy long enough to lose substantial weight.
The three BMI pathways
| Pathway | BMI at therapy initiation | Required diagnosis |
|---|---|---|
| A | BMI ≥ 35 (obesity class II) | None additional required |
| B | BMI ≥ 30 (obesity class I) | At least one of: HFpEF, uncontrolled hypertension (SBP >140 or DBP >90 on ≥2 antihypertensives), CKD stage 3a+ |
| C | BMI ≥ 27 (overweight) | At least one of: prediabetes (ADA criteria), prior MI, prior stroke, symptomatic peripheral artery disease |
How the timing rule creates a trap
CMS's FAQ gives a specific example: if a beneficiary started GLP-1 therapy in September 2024 with a BMI of 37 and now has a BMI of 34 at the time of a July 2026 PA request, the prescribing provider must attest that the BMI was ≥35 at the time therapy was initiated. The current BMI of 34 does not disqualify the patient — but the provider must document the historical BMI.
This becomes a problem in three scenarios:
No documented baseline BMI. If the initiating provider did not record a BMI in the medical record at the time of GLP-1 initiation — or the record is from a different health system — the attestation may not be supportable.
Therapy initiated before the program was announced. CMS allows beneficiaries to count therapy initiation that occurred before the Bridge program launch. But a patient who started semaglutide in 2022 for type 2 diabetes and later switched to Wegovy for weight management may have ambiguous initiation dates. The provider must identify the date therapy was initiated "for the purpose of reducing excess body weight and maintaining weight reduction."
Weight loss has moved the patient below the BMI threshold. A patient who started at BMI 30 with an HFpEF diagnosis and has since lost enough weight to reach BMI 26 is still eligible — but only if the PA attests to the BMI at initiation, not the current BMI. Some providers will incorrectly document the current BMI and trigger a denial.
Hub teams should instruct providers to document the BMI at the time of GLP-1 therapy initiation for weight management specifically, not the current BMI, and to include the supporting medical record reference in the PA submission.
Trap 3: Diagnosis mismatch and the "covered use" redirect
The Bridge only covers GLP-1 drugs when used "to reduce excess body weight and maintain weight reduction in combination with current and ongoing lifestyle modification." If a beneficiary's GLP-1 is prescribed for a Medicare-covered indication — type 2 diabetes, cardiovascular disease risk reduction, or obstructive sleep apnea — CMS expects the drug to be covered through the patient's regular Part D plan, not the Bridge.
When this redirect breaks the patient pathway
Consider a patient with type 2 diabetes who is prescribed Ozempic (semaglutide 1 mg injection) for glycemic control. Ozempic is not an eligible Bridge medication — only Wegovy, Zepbound, and Foundayo are. Even if the patient meets BMI criteria, the Bridge will not cover Ozempic because it is not on the eligible drug list.
Conversely, a patient prescribed Wegovy for cardiovascular risk reduction (the SELECT trial indication, which CMS recognizes as a covered Part D use) will be redirected to their Part D plan rather than the Bridge. The Bridge only covers GLP-1 drugs "when used for obesity." The same Wegovy prescription for the same patient could be processed through Part D if the indication is cardiovascular risk reduction, or through the Bridge if the indication is weight management. The PA must specify the obesity indication.
The dual-indication documentation problem
Some patients legitimately qualify for GLP-1 therapy under both a covered Part D indication and the Bridge obesity indication. Wegovy is FDA-approved for both cardiovascular risk reduction and chronic weight management. The provider must choose which indication to document on the Bridge PA. If the PA references cardiovascular risk reduction as the primary indication, the central processor will redirect to Part D. If the PA references obesity with lifestyle modification as the primary indication and includes the qualifying BMI and comorbidity data, the Bridge should process.
Hub teams should ensure the PA form explicitly states the indication as "reduction of excess body weight and maintenance of weight reduction" and does not lead with cardiovascular or diabetes language that could trigger a redirect.
Trap 4: Drug-eligibility restriction
The Bridge currently covers only three products:
- Wegovy (semaglutide injection, all strengths; and Wegovy oral tablets if approved)
- Zepbound (tirzepatide KwikPen, all strengths)
- Foundayo (orforglipron, oral GLP-1, if FDA-approved and added by CMS)
The following GLP-1 drugs are not covered by the Bridge:
- Ozempic (semaglutide injection) — approved for type 2 diabetes, not obesity
- Mounjaro (tirzepatide injection) — approved for type 2 diabetes, not obesity
- Rybelsus (oral semaglutide) — approved for type 2 diabetes, not obesity
- Trulicity (dulaglutide) — approved for type 2 diabetes and CV risk reduction, not obesity
- Compounded semaglutide or tirzepatide — not FDA-approved products
The off-label and biosimilar gap
If a biosimilar or interchangeable version of semaglutide or tirzepatide receives FDA approval for obesity during the Bridge period, CMS has not yet clarified whether it would automatically become an eligible Bridge drug. The FAQ states that eligible drugs include Wegovy, Zepbound, and "at this time" suggests the list may expand, but there is no guarantee.
Trap 5: The $50 copay does not count toward TrOOP
The Bridge operates outside Part D. The $50 monthly copay does not count toward the beneficiary's Part D deductible or the $2,100 out-of-pocket maximum in 2026 ($2,400 in 2027). This is not technically an ineligibility trap, but it creates a financial surprise that can feel like one.
A beneficiary who is also taking other expensive Part D drugs may reasonably expect the $50 Bridge copay to count toward the $2,100 cap. It does not. The beneficiary could pay $50/month for Wegovy through the Bridge from July through December ($300 total) and also pay out-of-pocket for other Part D drugs until reaching $2,100. The total annual outlay could exceed $2,400 even though the Part D cap is $2,100, because the Bridge copay is separate.
Hub teams should explain this clearly to patients. The Bridge is not a Part D benefit. The $50 copay is a demonstration-specific cost that exists in parallel with, not within, the Part D benefit structure.
Trap 6: The BALANCE transition cliff
The Bridge was originally scheduled to end December 31, 2026, with the BALANCE Model taking over on January 1, 2027. CMS extended the Bridge through December 31, 2027, after the BALANCE Model was delayed. But the long-term access path remains uncertain.
If the BALANCE Model does not launch in 2028 — or if a beneficiary's Part D plan sponsor does not participate in BALANCE — the patient could lose GLP-1 access entirely after the Bridge ends. The Bridge PA does not guarantee ongoing coverage. Each PA covers a defined supply period, and reauthorization is subject to continued eligibility.
Hub teams should not assume Bridge coverage extends beyond December 31, 2027. Patients who will need long-term GLP-1 therapy should be counseled about the uncertain 2028 coverage landscape and the possibility that BALANCE participation by their Part D plan will determine future access.
Pre-submission verification checklist for hub teams
Before a provider submits a Bridge PA to the central processor, the hub should verify each of the following:
| Verification | Source | Common failure |
|---|---|---|
| Plan type is eligible (PDP, MA-PD HMO/PPO, SNP, EGWP, LI NET) | Member ID card, plan enrollment verification | PFFS, PACE, cost contract, prepayment plan — patient has "Part D" but wrong plan type |
| Drug is on Bridge eligible list (Wegovy, Zepbound, Foundayo) | Prescription, FDA labeling | Ozempic, Mounjaro, Rybelsus prescribed for weight loss |
| Indication documented as weight management with lifestyle modification | PA form, medical record | Provider documents cardiovascular risk reduction or diabetes as primary indication |
| BMI at therapy initiation meets threshold (≥35, ≥30 with qualifying comorbidity, or ≥27 with qualifying comorbidity) | Medical record from initiation date | Provider documents current BMI instead of initiation BMI |
| Qualifying comorbidity documented if BMI <35 | Diagnosis codes, lab values, clinical notes | HFpEF, uncontrolled HTN, CKD 3a+, prediabetes, prior MI/stroke/PAD not in record |
| Patient is ≥18 years old | Date of birth | Rare but possible for pediatric patients |
| GLP-1 was not previously covered through Part D for a Medicare-covered use | Claims history | Patient was already receiving Wegovy through Part D for CV risk reduction |
What happens when the PA is denied
When the central processor denies a Bridge PA, the denial pathways are limited. Because the Bridge operates outside Part D, standard Part D appeals processes (redetermination by the plan, independent review entity) do not apply. CMS has not yet published detailed Bridge-specific appeal procedures.
The practical options after a Bridge PA denial are:
- Correct and resubmit. If the denial is due to missing documentation (BMI timing, diagnosis, plan type), the provider can gather the correct records and resubmit.
- Redirect to Part D. If the patient's GLP-1 indication qualifies as a Medicare-covered use (CV risk reduction, type 2 diabetes, sleep apnea), the provider can submit a standard Part D PA to the patient's plan.
- Manufacturer patient assistance. If neither the Bridge nor Part D covers the drug, the patient may qualify for a manufacturer copay assistance program or patient assistance program, though these typically do not cover the full cost.
Sources
- CMS. "Medicare GLP-1 Bridge." https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge. Accessed May 2026.
- CMS. "Information for Medicare Beneficiaries: Medicare GLP-1 Bridge." https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-medicare-beneficiaries. Accessed May 2026.
- Reed Smith. "Frequently Asked Questions Related to the Medicare GLP-1 Bridge." https://www.reedsmith.com/our-insights/blogs/health-industry-washington-watch/102mm7i/cms-provides-details-for-medicare-glp-1-bridge-coverage-for-eligible-part-d-ben. 2026.
- KFF. "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid." https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid. 2026.
- Boomer Benefits. "Medicare GLP-1 Bridge Program Explained." https://boomerbenefits.com/medicare-glp-1-bridge-program-explained. 2026.
- Solace Health. "Medicare Now Covers GLP-1s for $50/Month: Here's How to Qualify." https://www.solace.health/articles/medicare-glp-1-bridge-program. 2026.
- AMCP. "CMS Releases Frequently Asked Questions on the Medicare GLP-1 Bridge." https://www.amcp.org/regulatory-newsbreak-cms-releases-frequently-asked-questions-medicare-glp-1-bridge. 2026.
- Obesity Medicine Association. "CMS Announces Changes to Medicare Coverage of GLP-1 Medications for 2027." https://obesitymedicine.org/blog/cms-announces-changes-to-medicare-coverage-of-glp-1-medications-for-2027. 2026.
- Parrott Benefit Group. "CMS to Offer $50 Per Month GLP-1 Access Starting July 1." https://parrottbenefitgroup.com/cms-to-offer-50-per-month-glp-1-access-starting-july-1. 2026.
This article is for informational purposes only and does not constitute medical, legal, or reimbursement advice. Coverage and eligibility are subject to change based on CMS guidance.
